LUPUS NEPHRITIS - WHO CLASS III
Clinical trials for LUPUS NEPHRITIS - WHO CLASS III explained in plain language.
Never miss a new study
Get alerted when new LUPUS NEPHRITIS - WHO CLASS III trials appear
Sign up with your email to follow new studies for LUPUS NEPHRITIS - WHO CLASS III, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental CAR t therapy takes aim at lupus kidney disease
Disease control OngoingThis early-phase study tests a new treatment called KYV-101 for people with lupus nephritis (kidney inflammation from lupus) that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells. The main goal…
Matched conditions: LUPUS NEPHRITIS - WHO CLASS III
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 26, 2026 09:42 UTC
-
Immune cell therapy takes on tough lupus cases
Disease control OngoingThis early-stage study tests a new treatment called AB-101, made from natural killer cells, for people with severe lupus that hasn't responded to standard therapies. The treatment is given alone or with a B-cell depleting antibody to try to control the disease. The main goals are…
Matched conditions: LUPUS NEPHRITIS - WHO CLASS III
Phase: PHASE1 • Sponsor: Artiva Biotherapeutics, Inc. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC